We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
-10.74%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$582M
AUM Growth
-$123M
Cap. Flow
+$8.6M
Cap. Flow %
1.48%
Top 10 Hldgs %
47.58%
Holding
53
New
6
Increased
26
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$33M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$15.8M
3
JANX icon
Janux Therapeutics
JANX
+$12.7M
4
UTHR icon
United Therapeutics
UTHR
+$12.3M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.2M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$26.9M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$24.4M
3
IRON icon
Disc Medicine
IRON
+$22M
4
SRRK icon
Scholar Rock
SRRK
+$18M
5
AKRO
Akero Therapeutics
AKRO
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$57.9M 9.95%
7,648,268
– –
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$12.3B
$33.3M 5.72%
+100,415
New +$33M
ZLAB icon
3
Zai Lab
ZLAB
$2.93B
$30.1M 5.18%
833,659
+33,659
+4% +$1.04M
EWTX icon
4
Edgewise Therapeutics
EWTX
$4.64B
$24.3M 4.18%
1,105,444
+26,128
+2% +$685K
LNTH icon
5
Lantheus
LNTH
$6.58B
$22.7M 3.9%
232,387
-3,826
-2% -$358K
PTCT icon
6
PTC Therapeutics
PTCT
$5.85B
$22.4M 3.85%
439,977
+5,210
+1% +$260K
NTRA icon
7
Natera
NTRA
$47B
$22.2M 3.82%
157,047
-3,579
-2% -$575K
TRVI icon
8
Trevi Therapeutics
TRVI
$2.39B
$21.6M 3.71%
3,428,366
+333,470
+11% +$1.59M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$9B
$21.2M 3.64%
631,964
+14,929
+2% +$558K
RNAM
10
DELISTED
Avidity Biosciences
RNAM
$21.1M 3.62%
714,224
+11,243
+2% +$350K
GH icon
11
Guardant Health
GH
$21.7B
$18.9M 3.24%
442,656
-10,083
-2% -$435K
UTHR icon
12
United Therapeutics
UTHR
$22.1B
$18.2M 3.12%
58,907
+35,907
+156% +$12.3M
SPRY icon
13
ARS Pharmaceuticals
SPRY
$586M
$16.5M 2.84%
+1,313,104
New +$15.8M
CMPX icon
14
Compass Therapeutics
CMPX
$432M
$16M 2.76%
8,442,783
-125,113
-1% -$333K
JANX icon
15
Janux Therapeutics
JANX
$1.1B
$15.3M 2.63%
567,193
+337,193
+147% +$12.7M
RARE icon
16
Ultragenyx Pharmaceutical
RARE
$2.52B
$14.4M 2.48%
398,445
+7,427
+2% +$309K
MLTX icon
17
MoonLake Immunotherapeutics
MLTX
$1.28B
$12.3M 2.12%
316,049
+819
+0.3% +$35.3K
WVE icon
18
Wave Life Sciences
WVE
$993M
$12.2M 2.1%
1,509,580
+20,343
+1% +$222K
RVMD icon
19
Revolution Medicines
RVMD
$44.6B
$11.2M 1.93%
317,083
+3,266
+1% +$133K
ALKS icon
20
Alkermes
ALKS
$7.95B
$11.1M 1.92%
+337,603
New +$11M
OLMA icon
21
Olema Pharmaceuticals
OLMA
$899M
$11M 1.89%
2,930,446
+17,896
+0.6% +$90K
RCKT icon
22
Rocket Pharmaceuticals
RCKT
$424M
$10.8M 1.86%
1,618,265
+597,706
+59% +$5.91M
ITOS
23
DELISTED
iTeos Therapeutics
ITOS
$10.4M 1.79%
1,745,943
– –
RNAC icon
24
Cartesian Therapeutics
RNAC
$290M
$10.4M 1.79%
790,779
+69,640
+10% +$1.24M
TWST icon
25
Twist Bioscience
TWST
$8.87B
$10.3M 1.76%
261,215
-6,282
-2% -$283K
1
2 3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q1 2025 Portfolio in Review

As of Q1 2025, MPM BioImpact held 53 positions worth $582M, down 17% from $704M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

MPM BioImpact's Q1 2025 filing shows 6 new, 26 increased, 8 reduced and 10 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 100,415 shares worth $33.3M. The largest sale was Insmed, an estimated $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q1 2025 buy was Madrigal Pharmaceuticals: 100,415 shares worth $33.3M.
  • MPM BioImpact added most to Janux Therapeutics in Q1 2025, an estimated $12.7M increase.
  • MPM BioImpact's biggest Q1 2025 reduction was ALX Oncology, cutting an estimated $1.01M.
  • MPM BioImpact fully exited Insmed in Q1 2025, selling an estimated $26.9M.
  • MPM BioImpact's ten largest holdings make up 48% of its $582M portfolio in Q1 2025.
  • MPM BioImpact opened 6 new positions and closed 10 in Q1 2025.
  • MPM BioImpact's portfolio value fell 17% quarter-over-quarter to $582M.

Based on MPM BioImpact's 13F filing for Q1 2025, filed 15 May 2025.